Tyverb in combination with trastuzumab has demonstrated efficacy in treating HER2+ HR-negative (HR-) metastatic breast cancer in patients who have progressed on prior trastuzumab-based therapy in combination with chemotherapy.1

The clinical efficacy of Tyverb in combination with trastuzumab was evaluated in the phase III EGF104900 study.1

Patients must have received prior treatment for their metastatic disease with trastuzumab and chemotherapy. In this study, a sub-group of 150 patients had HER2+ HR- metastatic breast cancer; the post-hoc analysis performed on this cohort is presented here.2

Effects on progression-free survival

In a post-hoc analysis of women with HER2+ HR- metastatic breast cancer, progression-free survival (PFS) outcome data support the use of Tyverb and trastuzumab in combination as a dual HER2 blockade in patients with heavily pretreated HER2+ HR- metastatic breast cancer.1,2

PFS in HER2+, HR- patients treated with Tyverb in combination with trastuzumab versus lapatinib monotherapy 

Information about the adverse events of lapatinib and trastuzumab are available in the safety section.

*Lapatinib is not approved for use as a single agent.

Tyverb in combination with trastuzumab: safety

References: 1. Tyverb® (lapatinib) Summary of Product Characteristics. Camberley, UK: Novartis Europharm Limited; 11 August 2015. 2. European Medicines Agency June 2013. Assessment report: Tyverb. EMA/H/C/795/II/22. Available from (Accessed 4 September 2015).